These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 16440808)
1. [Oral administration of arsenic trioxide induced molecular remission in relapsed acute promyelocytic leukemia]. Fukuda M Rinsho Ketsueki; 2005 Nov; 46(11):1223-5. PubMed ID: 16440808 [TBL] [Abstract][Full Text] [Related]
2. [Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)]. Tanaka Y; Komatsu H; Ishii K; Nakamura F; Hayashi T; Sawada H; Ono Y; Imanaka T Rinsho Ketsueki; 2000 Apr; 41(4):354-7. PubMed ID: 10846468 [TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639 [TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report. Bergstrom SK; Gillan E; Quinn JJ; Altman AJ J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675 [TBL] [Abstract][Full Text] [Related]
5. [Therapeutic effects of combination of arsenic trioxide with low-dose all-trans retinoic acid on induction of remission acute promyeloeytic leukemia]. Wang GJ; Li W; Cui JW; Gao SJ; Yao C; Jiang ZY; Song YQ; Yuan CJ; Yang Y; Liu ZL Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(16):1093-6. PubMed ID: 16029564 [TBL] [Abstract][Full Text] [Related]
6. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Au WY; Chim CS; Lie AK; Liang R; Kwong YL Br J Haematol; 2002 Apr; 117(1):130-2. PubMed ID: 11918543 [TBL] [Abstract][Full Text] [Related]
7. [Successful bone marrow transplantation with a matched unrelated donor in an acute promyelocytic leukemia patient after reinduction therapy with arsenic trioxide]. Iguchi T; Yokoyama K; Miyamoto K; Aisa Y; Shimizu T; Mori T; Ikeda Y; Okamoto S Rinsho Ketsueki; 2004 Jan; 45(1):75-7. PubMed ID: 14999939 [TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation. Leoni F; Gianfaldoni G; Annunziata M; Fanci R; Ciolli S; Nozzoli C; Ferrara F Haematologica; 2002 May; 87(5):485-9. PubMed ID: 12010661 [TBL] [Abstract][Full Text] [Related]
9. Successful treatment of all-trans retinoic acid resistant and chemotherapy naïve acute promyelocytic patients with arsenic trioxide--two case reports. Lin CP; Huang MJ; Chang IY; Lin WY Leuk Lymphoma; 2000 Jun; 38(1-2):191-4. PubMed ID: 10811462 [TBL] [Abstract][Full Text] [Related]
10. Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients. Au WY; Li CK; Lee V; Yuen HL; Yau J; Chan GC; Ha SY; Kwong YL Pediatr Blood Cancer; 2012 Apr; 58(4):630-2. PubMed ID: 21898784 [TBL] [Abstract][Full Text] [Related]
11. Induction, consolidation, and maintenance therapies with arsenic as a single agent for acute promyelocytic leukaemia in a 11-year follow-up. Aznab M; Rezaei M Hematol Oncol; 2017 Mar; 35(1):113-117. PubMed ID: 26310595 [TBL] [Abstract][Full Text] [Related]
12. Effects of arsenic trioxide administration styles on leukocytosis. Zhou J; Meng R; Sui XH; Meng L; Yang BF Chin Med Sci J; 2006 Jun; 21(2):111-4. PubMed ID: 16845799 [TBL] [Abstract][Full Text] [Related]
13. [Effects of combination therapy with all-trans retinoic acid and arsenic trioxide on acute promyelocytic leukemia]. Zhang GC; Zheng D; Li QH; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD Ai Zheng; 2004 Apr; 23(4):430-4. PubMed ID: 15087033 [TBL] [Abstract][Full Text] [Related]
14. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience. Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687 [TBL] [Abstract][Full Text] [Related]
15. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution. Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151 [TBL] [Abstract][Full Text] [Related]
16. A prospective, observational study of added medium-dose cytosine arabinoside versus As2O3 for elderly patients with acute promyelocytic leukemia. Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL Med Oncol; 2014 Oct; 31(10):233. PubMed ID: 25213763 [TBL] [Abstract][Full Text] [Related]
17. Early relapse after non myeloablative allogeneic stem cell transplantation in a patient with acute promyelocytic leukemia in complete molecular remission. Tavernier E; Thomas X Indian J Cancer; 2003; 40(4):140-3. PubMed ID: 14716110 [TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Powell BL; Moser B; Stock W; Gallagher RE; Willman CL; Stone RM; Rowe JM; Coutre S; Feusner JH; Gregory J; Couban S; Appelbaum FR; Tallman MS; Larson RA Blood; 2010 Nov; 116(19):3751-7. PubMed ID: 20705755 [TBL] [Abstract][Full Text] [Related]
19. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Au WY; Kumana CR; Kou M; Mak R; Chan GC; Lam CW; Kwong YL Blood; 2003 Jul; 102(1):407-8. PubMed ID: 12814916 [No Abstract] [Full Text] [Related]
20. Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia. Galimberti S; Papineschi F; Carmignani A; Testi R; Fazzi R; Petrini M Bone Marrow Transplant; 1999 Aug; 24(3):345-8. PubMed ID: 10455379 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]